Neogen Lifts FY2027 Outlook on Q1 Beat and New Imaging Partnership
NEOG has more than doubled off its 52-week low of $5.37 on elevated volume (2.0× avg).
Summary
Neogen reported Q1 FY2027 revenue of $222.8M (up 6.5% YoY), raised FY2027 guidance, and announced a strategic collaboration with Hinalea Imaging Corp. for digital food safety imaging.
Updates
· SEC 10-Q — The 10-Q reports Q1 FY2027 revenue of $222.8M, net loss of $11.9M, and operating loss of $1.8M.
Key Events · Earnings and Guidance · NEOG
-
Q1 Revenue Beats with 8.1% Core Growth
Revenue of $222.8M grew 6.5% YoY; core revenue growth was 8.1%, driven by Food Safety (+7.4%) and Animal Safety (+4.2%).
-
FY2027 Guidance Raised
Revenue guidance increased to $885–$890M (from $880–$885M) and Adjusted EBITDA to $181–$183M (from $180–$182M).
-
Hinalea Imaging Strategic Collaboration
Neogen announced a strategic collaboration with and equity investment in Hinalea Imaging Corp. to develop hyperspectral digital imaging solutions for food safety and quality inspection.
-
Petrifilm Manufacturing Transition On Track
First Petrifilm SKU fully validated in August 2026; multi-quarter manufacturing transition to Lansing site begins November 2026.
Analysis · NEOG · Life Sciences
Q1 FY2027 revenue came in at $222.8 million, up 6.5% year-over-year with core growth of 8.1%, prompting Neogen to raise full-year guidance for both revenue and Adjusted EBITDA. The company also unveiled a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety, and confirmed its Petrifilm manufacturing transition remains on track for November 2026. While the headline results were already reported by BusinessWire earlier today, the raised guidance and new partnership are incremental positives that reinforce the company's improving operational trajectory.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.6% of the 1679 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEOG was trading at $12.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.37 to $14.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.